Treatment decisions in chronic myeloid leukemia in the view of BCR-ABL1 mutations in practice

Abstract

Decisions in tailored treatment of chronic myeloid leukemia with second generation tyrosine kinase inhibitors and the use of BCR-ABL1 mutations results are demonstrated via casuistic.

Keywords

• chronic myeloid leukemia
• mutations BCR-ABL1
• treatment